Breaking Down Shandong Dongyue Organosilicon Materials Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Shandong Dongyue Organosilicon (300821.SZ) is a value play or a cautionary tale? The company posted RMB 1.13 billion in revenue in Q1 2025 (a 14.22% quarter-on-quarter decline) and TTM revenue of RMB 4.74 billion as of June 30, 2025 (down 6.22% YoY), despite delivering RMB 5.15 billion for full-year 2024 (+7.27% vs. 2023); profitability shows a slim Q1 net profit of RMB 36.82 million with a 0.97% net margin and operating margin of 3.03%, TTM net income of RMB 47.72 million (diluted EPS RMB 0.04) after a 2024 turnaround to RMB 56.76 million from a RMB 271.12 million loss in 2023, while balance sheet metrics reveal total assets of RMB 6.07 billion and shareholders' equity of RMB 4.90 billion as of September 30, 2025 and a market cap of RMB 10.52 billion (share price RMB 8.77 on Oct 22, 2025) with valuation extremes-TTM P/E at 224.00 versus a forward P/E of 4.02, P/B 2.17, EV/Revenue 1.74 and EV/EBITDA 19.59-set against risks like an approximately 96-97% decline in net profit for the nine months ended Sept 30, 2025, limited public debt metrics and sparse cash-flow disclosure, and potential upside from international expansion, new silicone product lines and a revenue-per-employee of roughly RMB 3.40 million across 1,222 staff; dive into the full analysis to weigh these numbers, valuation gaps and sector-specific risks.

Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) - Revenue Analysis

Recent top-line trends show momentum shift across quarters and years, with quarterly softness but a still-positive 2024 annual performance. Key metrics and context are listed below.

• Q1 2025 revenue: RMB 1.13 billion (14.22% decrease vs. previous quarter).
• TTM revenue as of 30 Jun 2025: RMB 4.74 billion (6.22% YoY decline).
• 2024 annual revenue: RMB 5.15 billion (7.27% increase vs. 2023).
• Revenue per employee: ~RMB 3.40 million (1,222 employees).
• Price-to-Sales (P/S): 2.53.
• Market capitalization (22 Oct 2025): RMB 10.52 billion.

For fuller corporate context and how the company generates revenue, see Shandong Dongyue Organosilicon Materials Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money.

Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) - Profitability Metrics

Key profitability indicators for Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) highlight a recovery in earnings and modest operating efficiency through recent reporting periods. Below are the principal metrics and their immediate implications.

• Q1 2025 net profit: RMB 36.82 million; profit margin: 0.97%.
• Q1 2025 operating margin: 3.03% - indicating operating profitability relative to revenue.
• TTM net income: RMB 47.72 million; diluted EPS (TTM): RMB 0.04.
• ROA: 0.77%; ROE: 0.89% - returns consistent with low-margin industrial specialty-chemicals operations.
• Full-year 2024 net profit: RMB 56.76 million versus a net loss of RMB 271.12 million in 2023 - a material turnaround.
• Basic EPS from continuing operations (2024): RMB 0.05 vs. loss per share RMB 0.23 in 2023.

• Turnaround context: the shift from a RMB 271.12 million loss in 2023 to RMB 56.76 million profit in 2024 sharply improved EPS and reduced cumulative impairment or one-off pressure on earnings.
• Profitability levels remain modest (sub-1% profit margin, low ROA/ROE), suggesting sensitivity to revenue changes and cost structure.
• Operating margin of 3.03% in Q1 2025 indicates operational leverage exists but limited room for margin expansion without pricing or cost improvements.

For the company's stated direction and values that may influence capital allocation and strategic choices affecting these metrics, see: Mission Statement, Vision, & Core Values (2026) of Shandong Dongyue Organosilicon Materials Co., Ltd.

Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) - Debt vs. Equity Structure

• Equity-dominant capital structure: shareholders' equity of RMB 4.90 billion represents ~80.7% of total assets, indicating a strong equity base.
• Low implied leverage: implied liabilities of RMB 1.17 billion suggest modest gearing; implied debt-to-equity ~0.24 supports a conservative leverage profile.
• Stability in debt levels: management has not reported material changes in debt over the past year, consistent with steady financial leverage.
• Equity growth: owners' equity rose from RMB 4.80 billion in 2023 to RMB 4.90 billion by 9/30/2025, signalling retained earnings accumulation and/or capital injections.
• Financing preference: patterns point to favoring equity financing over incremental debt, reducing dependence on external borrowings.
• Data limitations: the company has not disclosed detailed debt metrics (e.g., gross debt split, maturities, covenant structure), so assessment of refinancing risk and interest-rate sensitivity requires caution.

• Investor implications:
  • Lower financial risk from modest implied leverage, but verify actual gross debt and off‑balance-sheet obligations before sizing exposure.
  • Equity growth trend supports capital adequacy for operational needs and potential expansion without aggressive borrowing.
  • Conservative capital structure may limit return on equity in high-growth scenarios but enhances resilience in downturns.

Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) signal modest profitability and constrained return generation, while some important short-term and cash-flow details are missing.

• Current ratio and quick ratio: not provided - limits ability to assess short-term liquidity and working-capital sufficiency.
• Net profit margin: 0.97% - indicates low net profitability on sales, which can strain internal cash generation for liabilities.
• Operating margin: 3.03% - positive operational profitability that suggests some efficiency in core operations and potential to support liquidity if sustained.
• Return on assets (ROA): 0.77% - modest ability to convert assets into net income.
• Return on equity (ROE): 0.89% - low equity returns, implying limited shareholder value creation in the period measured.
• Market capitalization: RMB 10.52 billion (as of October 22, 2025) - reflects market valuation and investor view on size and prospects.
• Cash flow detail: absence of detailed cash flow statements restricts evaluation of solvency, debt servicing capacity, and true cash-generation dynamics.

• Strengths: positive operating margin (3.03%) and market cap (RMB 10.52B) suggest operational viability and investor recognition.
• Risks: low net margin, low ROA/ROE, and missing current/quick ratios and cash flow detail heighten uncertainty around short-term liquidity and long-term solvency.

Further context on corporate history, ownership and business model is available here: Shandong Dongyue Organosilicon Materials Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) - Valuation Analysis

• TTM P/E: 224.00 - unusually high, indicating depressed trailing earnings or one‑off losses and high market expectation vs recent profitability.
• Forward P/E: 4.02 - implies the market anticipates a substantial rebound in earnings over the next 12 months.
• P/B: 2.17 - the stock trades a little over twice book value, reflecting moderate premium to net assets.
• EV/Revenue: 1.74 - suggests the enterprise value is 1.74x annual revenues.
• EV/EBITDA: 19.59 - relatively elevated, implying either thin EBITDA margins historically or growth priced into future cash flows.

• Interpretation: The disparity between TTM P/E (224.00) and forward P/E (4.02) typically indicates either a recent earnings trough (one‑off charges, cyclical downturn) or anticipated strong operational recovery.
• Risk considerations: Elevated EV/EBITDA (19.59) versus EV/Revenue (1.74) underscores sensitivity to margin improvements; if EBITDA recovery fails to materialize, downside risk increases.
• Investor takeaway: Market capitalization of RMB 10.52 billion at RMB 8.77 per share implies investors are pricing in meaningful near‑term earnings upside despite current profitability challenges.

Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) - Risk Factors

Key quantitative indicators and qualitative concerns highlight elevated investor risk for Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ):

• Net profit collapse: reported decline of ~96.27% to 97.40% year-on-year for the nine months ended September 30, 2025, signaling severe near-term earnings stress.
• Modest trailing profitability: TTM net income of RMB 47.72 million with diluted EPS RMB 0.04-limited earnings cushion versus market expectations.
• Valuation risk: TTM P/E of 224.00, implying the market prices earnings growth that may be difficult to achieve given recent profit deterioration.
• Financial statement gaps: absence of published debt-to-equity ratio and lack of detailed cash flow statements restricts assessment of leverage, liquidity and solvency.
• Industry concentration: dependence on the organosilicon materials sector creates exposure to raw-material price swings, demand cyclicality and regulatory shifts.

Additional risk vectors to monitor:

• Commodity exposure: feedstock (silicon, methylchlorosilanes, etc.) price volatility can compress margins quickly.
• Regulatory & environmental compliance: tighter emissions, waste-handling or chemical safety rules could increase capex and operating costs.
• Customer concentration and order cyclicality: any large customer slowdown or inventory destocking in downstream industries (silicones, sealants, specialty chemicals) may materially affect revenues.
• Market sentiment sensitivity: with EPS at RMB 0.04, small earnings misses or guidance downgrades could produce outsized share-price moves given the 224x P/E.

For context on corporate direction and strategic priorities, see: Mission Statement, Vision, & Core Values (2026) of Shandong Dongyue Organosilicon Materials Co., Ltd.

Shandong Dongyue Organosilicon Materials Co., Ltd. (300821.SZ) - Growth Opportunities

• Projected net profit surge: management guidance indicates net profit for the year ended December 31, 2024 is expected to rise by approximately 119.18% to 122.87% versus the prior year - a material improvement that signals strong margin recovery or one‑off gains supporting reinvestment.
• International expansion: active initiatives in the United States, Belgium, Germany, India, South Korea and the United Arab Emirates broaden addressable markets and reduce concentration risk.
• Product development: pipeline includes silicone monomers, silicone intermediates and silicone rubbers aimed at higher‑value applications and diversified end uses.
• End‑market demand: growth drivers include construction, textiles, automotive and electronics sectors where organosilicon materials are increasingly specified for performance, durability and miniaturization needs.
• Operational focus: ongoing cost control and efficiency programs are expected to bolster margins and free cash flow, supporting capex and R&D for future growth.
• Strategic partnerships: local and international collaborations can accelerate market entry, technology transfer and scale‑up of new products.

• Topline & margin implications: a >100% swing in net profit year‑over‑year typically reflects either substantial sales growth, improved gross margins from product mix shifts (more silicone rubbers/monomers), one‑off non‑operating items, or a combination; investors should monitor quarterly revenue trends, gross margin expansion and SG&A trajectory to verify sustainability.
• Market penetration tactics: ramping distribution in Europe and North America, local certifications for electronics/automotive standards, and co‑development agreements with OEMs can accelerate adoption of new organosilicon formulations.
• R&D and capex prioritization: directing capex toward production lines for higher‑margin silicone intermediates and rubbers plus targeted R&D for specialty formulations will determine medium‑term margin expansion.